GVHD

Explore the most recent clinical developments in graft-versus-host disease (GVHD). Cancer Nursing Today provides up-to-date coverage of biomarkers for GVHD, chronic GVHD flares during immunosuppressive therapy, and more. From disease prevention in pediatric patients to drug evaluation for chronic GVHD, learn more about the evolution of GVHD care and research.

Individualized Anti-Thymocyte Globulin for GVHD Prevention in Pediatric HSCT

Individualized Anti-Thymocyte Globulin for GVHD Prevention in Pediatric HSCT

Patrick Daly

GVHD | August 3, 2022

According to a recent study in The Lancet Haematology, individualized dosing of anti-thymocyte globulin yielded significant improvements in early CD4+ T-cell immune reconstitution in pediatric hematopoietic stem cell transplantation (HSCT) recipients—without increasing the incidences of graft-versus-host disease (GVHD) and graft failure. The phase 2 trial, led by Rick Admiraal, MD, enrolled 58 pediatric patients between July 1, 2015 and August 22, 2018 at the University Medical Center Utrecht and the Princess Máxima Center for Pediatric Oncology. Anti-thymocyte globulin dosing was based on patients’ bodyweight, initial absolute lymphocyte count, and graft source—ranging from ...

Advertisement

Latest News

Individualized Anti-Thymocyte Globulin for GVHD Prevention in Pediatric HSCT

Individualized Anti-Thymocyte Globulin for GVHD Prevention in Pediatric HSCT

Patrick Daly

GVHD | August 3, 2022

Individualized ATG Dosing in HSCT

Adding Arsenic Trioxide to Corticosteroids in Chronic GVHD

Adding Arsenic Trioxide to Corticosteroids in Chronic GVHD

Patrick Daly

GVHD | August 3, 2022

Researchers found that combining arsenic trioxide with corticosteroids (CS) yielded a high response rate and rapid CS dose

Post-Transplant Cyclophosphamide or Tacrolimus and Methotrexate for GVHD Prevention

Post-Transplant Cyclophosphamide or Tacrolimus and Methotrexate for GVHD Prevention

Patrick Daly

GVHD | August 3, 2022

PTCy-based regimens appeared to significantly improve GVHD-free relapse-free survival

$Analyzing Ruxolitinib Outcomes in Steroid-Refractory Graft-Versus-Host Disease$

Analyzing Ruxolitinib Outcomes in Steroid-Refractory Graft-Versus-Host Disease

Patrick Daly

GVHD | August 3, 2022

Ruxolitinib therapy for steroid-refractory GVHD appeared to be more effective in patients with low-grade disease and ...

Back to the Basics: Pathophysiology of Acute GVHD

Back to the Basics: Pathophysiology of Acute GVHD

Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®

GVHD | July 25, 2022

The complex pathology of acute GVHD and what features are notable.

What’s New: Patient’s Perception of Caregiver Burden Post-Transplant

What’s New: Patient’s Perception of Caregiver Burden Post-Transplant

Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®

GVHD | July 25, 2022

Latest data on patients’ perception of caregiver burden after an allogeneic SCT, potential implications for oncology ...

Advertisement

Knowledge Hubs

Best Practices

Best Practices

Breast Cancer

Breast Cancer

Gyn-Onc

Gyn-Onc

Leukemia

Leukemia

Conference Highlights

Caregivers, Patients Have Different Decision-Making Support Needs

June 16, 2022

Nurse Monitoring Could Prevent Symptoms Related to Targeted, Immune Therapies

June 16, 2022

Automated Coaching with NP Follow-up Effectively Reduced Symptom Burden

June 16, 2022

Did Updated FDA Guidance Increase Inclusion of Patients With Brain Metastases in Breast Cancer Trials?

June 14, 2022

Palliative Care Consults Can Be Improved in Patients With Metastatic Breast Cancer

June 14, 2022

Study Identifies Ways to Increase Representation of Black Patients in Breast Cancer Clinical Trials

June 14, 2022

Caregivers, Patients Have Different Decision-Making Support Needs

June 16, 2022

Nurse Monitoring Could Prevent Symptoms Related to Targeted, Immune Therapies

June 16, 2022

Advertisement

Advertisement

Popular Stories

Researchers Discover Signature to Predict Response to Pembrolizumab

Keightley Amen

Conferences | June 2, 2022

The new data is being used to develop a biomarker tool to predict the efficacy of neoadjuvant pembrolizumab.

Study Examines COVID-19 Vaccine Efficacy in Patients With Breast Cancer

Keightley Amen

Conferences | June 2, 2022

Many studies are examining COVID-19's impact on particular subgroups of patients with cancer.

Recognizing Compassion Fatigue

Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®

Best Practices | April 22, 2022

Oncology nurses experience stress from many different directions—time pressures, nursing shortages, complex cancer ...

670 Madison Ave.

Manalapan, NJ 07726

Connect

Our Network

Blood Cancers Today

GU Oncology Now

Urban Health Today

About Us

Editorial Policy

© 2022 Mashup Media, LLC. All rights reserved.

Terms of Use | Privacy Policy